The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.
The payor has updated its medical policy to state that "the use of MammaPrint is considered medically necessary in women who are diagnosed with primary invasive breast cancer."
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
Agendia said that the guidelines reflect MammaPrint's rank as the only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT clinical trial.
The German Association of Gynecological Oncology included the breast cancer diagnostic in its annual update for cancer clinicians.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
One group pointed out differences between study group characteristics, while the other wondered about the role of patient preference.
Lebanon-based Cryogene and its subsidiary will distribute the gene expression-based test for breast cancer recurrence in the region.
Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
The MINDACT study of Agendia's MammaPrint has reported that using the tool could cut the use of chemotherapy in half.
Patients who've learned their genetic risk of disease worry about healthcare law changes in the US, Kaiser Health News reports.
Hopkins' Geoffrey Ling discusses the promise of genomic vaccines at Scientific American.
In Nature this week: mitochondrial genome of extinct South American ungulate, and more.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.